Rhizome AI

Rhizome AI is a specialized regulatory research agent for life-sciences teams. Its current product searches health-authority and related scientific/regulatory databases, returns source-linked answers and can turn research into structured deliverables rather than relying on a general web search.¹²

The current FAQ describes coverage across 17 countries, six international organizations, 117 databases and 51.6 million documents.² Those corpus-size figures are first-party scope claims, not an independent measurement of completeness or retrieval quality. Some non-English health authorities and datasets such as FAERS and MAUDE are reserved for Enterprise customers.² Rhizome also supports exports into Word, Excel and PowerPoint-style workflows.¹

The vendor markets answers as “hallucination-free” and says research can include very large citation sets.¹ Those are product claims, not independent accuracy guarantees. In regulatory work, citations make verification easier but do not remove the need to check the underlying authority, date, jurisdiction and applicability of an answer.

Rhizome publishes unusually clear pricing for a specialized enterprise research product. The Free tier is $0 with 10 messages per month. Project is $400 per month, Professional is $4,000 per year, Business is $30,000 per year for five seats, and Enterprise is custom-priced.¹

Higher tiers expand capacity and commercial controls. Business adds features such as invoicing, SSO/custom security and support, while Enterprise is the route for additional non-English health-authority coverage and other advanced datasets.¹² The free tier gives prospective users a meaningful way to inspect the workflow, but the jump to paid plans is substantial and should be evaluated against the volume and cost of existing regulatory-research work.

Rhizome's Privacy Policy, updated August 16, 2026, identifies Anthropic, OpenAI and Google Cloud among AI/service providers and states that customer data is not used to train AI models. It also says providers may retain inputs and outputs for up to 30 days for abuse monitoring, while uploaded documents are stored in Rhizome's infrastructure and account-related data may be retained for a limited period after termination.³

The Terms, updated May 15, 2026, draw an important boundary around the product: users must not upload patient-level information, protected health information or GDPR Article 9 special-category data. The service is positioned for research against published regulatory and scientific material, not for receiving or processing those sensitive datasets.⁴

Independent validation remains limited. G2 has a current exact-product Rhizome AI comparison/alternatives surface in life-sciences software, but the publicly readable page inspected did not expose a Rhizome-specific numeric rating or review count.⁵ No eligible current independent accuracy benchmark or numeric user-rating input was found. That matters because first-party claims about error-free retrieval or superior accuracy should not be treated as proven in a high-stakes regulatory workflow.

Rhizome is best suited to regulatory-affairs, quality and life-sciences R&D teams that repeatedly search multiple health-authority databases and need citations that can be traced back to primary material.² It is particularly useful when research must be converted into briefing material or office-document outputs rather than ending as a chat answer.

It is not a clinical decision-support system and should not be used as a repository for PHI or other prohibited special-category data.⁴ Teams that require independently validated accuracy, broad non-English regulator coverage on lower-cost plans, or a verified public API should evaluate those requirements explicitly before procurement.